ECSP056253A - Composicion farmaceutica que contiene un inhibidor de histona desacetilasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de histona desacetilasa

Info

Publication number
ECSP056253A
ECSP056253A EC2005006253A ECSP056253A ECSP056253A EC SP056253 A ECSP056253 A EC SP056253A EC 2005006253 A EC2005006253 A EC 2005006253A EC SP056253 A ECSP056253 A EC SP056253A EC SP056253 A ECSP056253 A EC SP056253A
Authority
EC
Ecuador
Prior art keywords
inhibitor
pharmaceutical composition
composition containing
histone
deacetilase
Prior art date
Application number
EC2005006253A
Other languages
English (en)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Akti Engesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Akti Engesellschaft filed Critical Schering Akti Engesellschaft
Publication of ECSP056253A publication Critical patent/ECSP056253A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Un fármaco anticáncer que tiene un efecto sinérgico debido a la utilización combinada de un derivado de histona desacetilasa tal como la N-(2-aminofenil)-4-[N-(piridín-3-ilmetoxicarbonil)aminometil] benzamida (MS-275) y otra sustancia anticáncer activa.
EC2005006253A 2003-05-26 2005-12-26 Composicion farmaceutica que contiene un inhibidor de histona desacetilasa ECSP056253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
ECSP056253A true ECSP056253A (es) 2006-10-25

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006253A ECSP056253A (es) 2003-05-26 2005-12-26 Composicion farmaceutica que contiene un inhibidor de histona desacetilasa

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN101322707A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2634765A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
MXPA06003222A (es) * 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
AU2006226861B2 (en) 2005-03-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
ES2481413T3 (es) 2006-02-14 2014-07-30 The President And Fellows Of Harvard College Inhibidores de histona desacetilasa
JP5497431B2 (ja) 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
JP5665740B2 (ja) 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
PE20110677A1 (es) * 2008-08-29 2011-09-16 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PT3354650T (pt) 2008-12-19 2022-06-20 Vertex Pharma Compostos úteis como inibidores da cinase atr
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
NZ596365A (en) * 2009-05-01 2013-11-29 Oncozyme Pharma Inc Pentamidine combinations for treating cancer
JP5586692B2 (ja) * 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EP2470173B1 (en) * 2009-08-25 2016-04-27 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
CA2850566C (en) 2011-09-30 2022-05-03 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
IN2014CN02501A (es) 2011-09-30 2015-06-26 Vertex Pharma
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
JP6320506B2 (ja) 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
EP3194387B1 (en) 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
PL348673A1 (en) * 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
DE60045890D1 (de) * 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
CN1387438A (zh) * 1999-11-10 2002-12-25 沃尼尔·朗伯公司 联合化学疗法
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
KR100938712B1 (ko) 2010-01-25
AU2004241873B8 (en) 2008-05-29
CU23490B7 (es) 2010-02-23
CN1794991A (zh) 2006-06-28
CR8163A (es) 2006-07-14
US20070098816A1 (en) 2007-05-03
TW200505424A (en) 2005-02-16
CA2634709A1 (en) 2004-12-02
CL2004001278A1 (es) 2005-05-06
PE20050206A1 (es) 2005-03-26
ZA200509515B (en) 2006-07-26
RU2005140570A (ru) 2006-06-10
NO20055417D0 (no) 2005-11-16
CA2634765A1 (en) 2004-12-02
NO20055417L (no) 2005-12-19
AU2004241873C1 (en) 2009-01-22
KR20060009371A (ko) 2006-01-31
MXPA05012345A (es) 2006-02-08
RS20050884A (en) 2008-04-04
CA2634766A1 (en) 2004-12-02
CO5660262A2 (es) 2006-07-31
BRPI0410959A (pt) 2006-07-04
AR045318A1 (es) 2005-10-26
MEP32308A (en) 2010-10-10
CN101322707A (zh) 2008-12-17
UA81499C2 (en) 2008-01-10
RU2322971C2 (ru) 2008-04-27
JP2006526031A (ja) 2006-11-16
IL171941A0 (en) 2006-04-10
EP1626719A1 (en) 2006-02-22
AU2004241873A1 (en) 2004-12-02
UY28330A1 (es) 2004-12-31
AU2004241873B2 (en) 2008-05-08
NZ543591A (en) 2009-09-25
CA2527191A1 (en) 2004-12-02
WO2004103369A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
ECSP056253A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
NO20044744L (no) Karbaminsyreforbindelser omfattende et piperazinledd som HDASinbibitorer
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
BR0308081A (pt) Inibidores de histona desacetilase
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
TW200510375A (en) New compounds
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
GB2427405A (en) Novel hydroxamates as therapeutic agents
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
EA200700067A1 (ru) Фармацевтическая композиция, содержащая производные пиперазина
ME01514B (me) Inhibitori histonske deacetilaze sa spojenom aktivnosti protiv histonskih deacetilaza klase-l i klase-IIB u kombinaciji sa inhibitorima proteasoma
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
AR049059A1 (es) Composiciones farmaceuticas de 4-(4bromo-2fluroanilino)-6-metoxi-7-(1-metilpiperidin-4ilmetoxi)quinazolina